Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Equity Average (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Equity Average for 12 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 21.79% year-over-year to $1.2 billion, compared with a TTM value of $1.2 billion through Dec 2025, down 21.79%, and an annual FY2025 reading of $1.4 billion, up 16.25% over the prior year.
  • Equity Average was $1.2 billion for Q4 2025 at Agios Pharmaceuticals, down from $1.3 billion in the prior quarter.
  • Across five years, Equity Average topped out at $2.0 billion in Q2 2021 and bottomed at $702.2 million in Q2 2024.
  • Average Equity Average over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
  • The sharpest move saw Equity Average skyrocketed 239.46% in 2021, then plummeted 41.98% in 2022.
  • Year by year, Equity Average stood at $1.3 billion in 2021, then fell by 19.94% to $1.1 billion in 2022, then fell by 21.07% to $848.9 million in 2023, then skyrocketed by 86.57% to $1.6 billion in 2024, then dropped by 21.79% to $1.2 billion in 2025.
  • Business Quant data shows Equity Average for AGIO at $1.2 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.4 billion in Q2 2025.